SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 6.2% – Here’s What Happened

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s stock price traded down 6.2% during mid-day trading on Wednesday . The company traded as low as $5.44 and last traded at $5.4580. 4,133,323 shares traded hands during trading, a decline of 51% from the average session volume of 8,485,182 shares. The stock had previously closed at $5.82.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $7.00.

SELLAS Life Sciences Group Trading Down 7.0%

The company has a fifty day moving average of $4.27 and a 200-day moving average of $2.72. The stock has a market cap of $771.17 million, a PE ratio of -19.28 and a beta of 2.18.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Axxcess Wealth Management LLC acquired a new stake in shares of SELLAS Life Sciences Group during the third quarter worth about $26,000. Larson Financial Group LLC acquired a new position in shares of SELLAS Life Sciences Group in the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets increased its stake in SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after buying an additional 9,299 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the 4th quarter worth approximately $38,000. Finally, Beacon Pointe Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the 4th quarter worth approximately $38,000. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.